Does Fesoterodine Have a Role in the Treatment of Poorly Managed Patients With Overactive Bladder?

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s40032
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome

International Neurourology Journal
NeurologyUrology
2015English

Does Sacral Pulsed Electromagnetic Field Therapy Have a Better Effect Than Transcutaneous Electrical Nerve Stimulation in Patients With Neurogenic Overactive Bladder?

Arab Journal of Urology
Urology
2017English

Dealing With Complex Overactive Bladder Syndrome Patient Profiles With Focus on Fesoterodine: In or Out of the EAU Guidelines?

Research and Reports in Urology
Urology
2017English

Botulinum Toxin a for the Treatment of Overactive Bladder

Toxins
MutagenesisToxicologyHealth
2016English

OnabotulinumtoxinA for the Treatment of Overactive Bladder

Research and Reports in Urology
Urology
2014English

Mp65-16 Predictor Factors for Successful Treatment of Solifenacin in Patients With Overactive Bladder

Journal of Urology
Urology
2016English

Factors Associated With Dose Escalation of Fesoterodine for Treatment of Overactive Bladder in People >65 Years of Age: A Post Hoc Analysis of Data From the SOFIA Study

Neurourology and Urodynamics
NeurologyUrology
2018English

Solifenacin in Multiple Sclerosis Patients With Overactive Bladder: A Prospective Study

Advances in Urology
GynecologyUrologyObstetrics
2011English

Transdermal Oxybutynin: What Role in the Management of Overactive Bladder?

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy